Benzinga | Jul 14, 2021 04:57AM EDT

RBC Capital Initiates Coverage On ResMed with Underperform Rating, Announces Price Target of $223

RBC Capital initiates coverage on ResMed (NYSE:RMD) with a Underperform rating and announces Price Target of $223.